---
title: "Aclaris Therapeutics, Summit Therapeutics And Other Big Stocks Moving Lower In Monday’s Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305677842.md"
description: "U.S. stock futures fell in Monday's pre-market session, with the Nasdaq 100 dropping over 1%. Aclaris Therapeutics plunged 21% after its Phase 2 dermatitis trial failed. Summit Therapeutics declined 17% following an FDA rejection of its lung cancer treatment. Other notable losers included Quanex Building Products (-19.1%), Helus Pharma (-12%), and Strive, Inc. (-9.1%), amid broader market weakness and specific corporate setbacks."
datetime: "2026-11-16T13:01:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305677842.md)
  - [en](https://longbridge.com/en/news/305677842.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305677842.md)
generator: "portal-rs"
---

# Aclaris Therapeutics, Summit Therapeutics And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling over 1% on Monday.

Shares of **Aclaris Therapeutics, Inc.** (NASDAQ:ACRS) fell sharply in pre-market trading after the company announced that its Phase 2 ADMIRATION trial of bosakitug in atopic dermatitis missed its primary and secondary endpoints.

Aclaris Therapeutics shares dipped 20.8% to $3.1017 in pre-market trading.

Here are some other stocks moving lower in pre-market trading.

-   **Quanex Building Products Corporation** (NYSE:NX) dipped 19.1% to $15.52 in pre-market trading.
-   **Summit Therapeutics Inc.** (NASDAQ:SMMT) declined 17% to $11.75 in pre-market trading after the company announced that its lung cancer treatment ivonescimab can’t be approved by the FDA in its current form, as substantial evidence of effectiveness has not been established.
-   **Helus Pharma Inc** (NASDAQ:HELP) declined 12% to $7.99 in pre-market trading after announcing topline results from its APPROACH Phase 3 study evaluating HLP003 for adults with major depressive disorder.
-   **Strive, Inc**. (NASDAQ:ASST) fell 9.1% to $19.42 in pre-market trading amid a decline in Bitcoin prices.
-   **Forward Industries, Inc**. (NASDAQ:FWDI) dipped 9.1% to $4.4907 in pre-market trading.
-   **POET Technologies Inc**. (NASDAQ:POET) declined 8.7% to $4.68 in pre-market trading following weak quarterly sales.
-   **T1 Energy Inc.** (NYSE:TE) fell 8.6% to $1.74 in pre-market trading following a 3% decline on Friday.
-   **Circle Internet Group** (NASDAQ:CRCL) fell 8.5% to $56.93 in pre-market trading.
-   **Hyperliquid Strategies Inc**. (NASDAQ:PURR) fell 8.4% to $7.97 in pre-market trading.
-   **Bitmine Immersion Technologies, Inc**. (NASDAQ:BMNR) fell 8% to $16.15 in pre-market trading amid a decline in Bitcoin prices.
-   **Windward Bio Group AG** (NASDAQ:WWB) dipped 7% to $26.50 in pre-market trading after surging around 68% on Friday.

*Photo via Shutterstock*

### Related Stocks

- [ACRS.US](https://longbridge.com/en/quote/ACRS.US.md)
- [ASST.US](https://longbridge.com/en/quote/ASST.US.md)
- [BMNR.US](https://longbridge.com/en/quote/BMNR.US.md)
- [BMNRD.US](https://longbridge.com/en/quote/BMNRD.US.md)
- [CRCL.US](https://longbridge.com/en/quote/CRCL.US.md)
- [FORD.US](https://longbridge.com/en/quote/FORD.US.md)
- [FREY.US](https://longbridge.com/en/quote/FREY.US.md)
- [FWDI.US](https://longbridge.com/en/quote/FWDI.US.md)
- [NX.US](https://longbridge.com/en/quote/NX.US.md)
- [POET.US](https://longbridge.com/en/quote/POET.US.md)
- [PURR.US](https://longbridge.com/en/quote/PURR.US.md)
- [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md)
- [TE.US](https://longbridge.com/en/quote/TE.US.md)
- [WWB.US](https://longbridge.com/en/quote/WWB.US.md)
- [BMNG.US](https://longbridge.com/en/quote/BMNG.US.md)
- [BMNU.US](https://longbridge.com/en/quote/BMNU.US.md)
- [BMNZ.US](https://longbridge.com/en/quote/BMNZ.US.md)
- [BNMC.US](https://longbridge.com/en/quote/BNMC.US.md)
- [CCUP.US](https://longbridge.com/en/quote/CCUP.US.md)
- [CIR.US](https://longbridge.com/en/quote/CIR.US.md)
- [CRCA.US](https://longbridge.com/en/quote/CRCA.US.md)
- [CRCD.US](https://longbridge.com/en/quote/CRCD.US.md)
- [CRCG.US](https://longbridge.com/en/quote/CRCG.US.md)
- [CRCO.US](https://longbridge.com/en/quote/CRCO.US.md)
- [ICRC.US](https://longbridge.com/en/quote/ICRC.US.md)
- [POEL.US](https://longbridge.com/en/quote/POEL.US.md)
- [PUR.US](https://longbridge.com/en/quote/PUR.US.md)
- [TEUP.US](https://longbridge.com/en/quote/TEUP.US.md)
- [YBMN.US](https://longbridge.com/en/quote/YBMN.US.md)
- [HELP.US](https://longbridge.com/en/quote/HELP.US.md)

## Related News & Research

- [FDA rejects Summit’s ivonescimab application for lung cancer](https://longbridge.com/en/news/305649863.md)
- [POET: Record revenue and expanding capacity support a 2027 production ramp amid supply constraints](https://longbridge.com/en/news/305671501.md)
- [Aclaris Therapeutics starts Phase 2b trial of modzatinib for lichen planus](https://longbridge.com/en/news/305637484.md)
- [Aclaris Therapeutics Participates in Jefferies Global Healthcare Conference Fireside Chat](https://longbridge.com/en/news/305317561.md)
- [Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application](https://longbridge.com/en/news/305571538.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**